Topic
Topic
REZOLVE-AA topline data show rezpegaldesleukin produces durable hair regrowth in alopecia areata, per Dermatology Times — a sustained-response signal pointing toward long-term disease modification.
Biomarker data presented late-breaking at EADV Congress 2026 show rezpegaldesleukin produces early molecular responses across mul…
New rezpegaldesleukin data presented at EADV Congress 2026 support long-term durability and disease improvement in both alopecia…
Rezpegaldesleukin delivered durable hair regrowth in the REZOLVE-AA alopecia areata trial, strengthening the case for selective I…
New rezpegaldesleukin data supporting long-term durability and disease improvement in alopecia areata and atopic dermatitis will…
Nektar Therapeutics says rezpegaldesleukin produced atopic dermatitis improvements as early as Week 2, accompanied by molecular c…
Week-2 serum biomarker shifts — rising IL-10 and TGFΒ1, falling TARC — predicted Week-16 EASI gains in rezpegaldesleukin-treated…
Nektar Therapeutics will give three oral presentations on rezpegaldesleukin at the EADV Congress 2026, with titles, endpoints and…